Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer

TATSURO TAMURA, MASAICHI OHIRA, HIROAKI TANAKA, KAZUYA MUGURUMA, TAKAHIRO TOYOKAWA, NAOSHI KUBO, KATSUNOBU SAKURAI, RYOSUKE AMANO, KENJIRO KIMURA, MASATSUNE SHIBUTANI, KIYOSHI MAEDA and KOSEI HIRAKAWA
Anticancer Research October 2015, 35 (10) 5369-5376;
TATSURO TAMURA
Department of Surgical Oncology, Osaka City University, Graduate School of Medicine, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAICHI OHIRA
Department of Surgical Oncology, Osaka City University, Graduate School of Medicine, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: masaichi@med.osaka-cu.ac.jp
HIROAKI TANAKA
Department of Surgical Oncology, Osaka City University, Graduate School of Medicine, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUYA MUGURUMA
Department of Surgical Oncology, Osaka City University, Graduate School of Medicine, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAHIRO TOYOKAWA
Department of Surgical Oncology, Osaka City University, Graduate School of Medicine, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NAOSHI KUBO
Department of Surgical Oncology, Osaka City University, Graduate School of Medicine, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATSUNOBU SAKURAI
Department of Surgical Oncology, Osaka City University, Graduate School of Medicine, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RYOSUKE AMANO
Department of Surgical Oncology, Osaka City University, Graduate School of Medicine, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENJIRO KIMURA
Department of Surgical Oncology, Osaka City University, Graduate School of Medicine, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASATSUNE SHIBUTANI
Department of Surgical Oncology, Osaka City University, Graduate School of Medicine, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KIYOSHI MAEDA
Department of Surgical Oncology, Osaka City University, Graduate School of Medicine, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOSEI HIRAKAWA
Department of Surgical Oncology, Osaka City University, Graduate School of Medicine, Osaka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: The cell surface receptor programmed death-1 (PD1) and its ligand (PDL1) have been detected in various cancer types. It has been reported that expression of PDL1 and PD1 in a tumor is associated with poor prognosis of the patient. In the present study, we retrospectively examined tumor expression of PDL1 and intratumoral PD1+ cell infiltration, and assessed their relationship with patient prognosis according to the pathological stage of gastric cancer. Materials and Methods: PDL1 and PD1 expression in primary tumors from 431 patients was evaluated using immunohistochemistry. The association between the expression of PDL1/PD1 and clinicopathological features was assessed. Results: High expression of PDL1 was observed in 128 (29.6%) patients. PDL1 expression was correlated with tumor infiltration of PD1+ cells. In multivariate analysis, PDL1 expression was associated with worse overall survival. In subset analysis, PDL1 expression was significantly associated with survival in patients with stage II/III gastric cancer. In conclusion, PDL1 was an independent prognostic factor for patients with stage II/III gastric cancer. Our results suggested that patients with stage II/III gastric cancer might be appropriate for PD1/PDL1-targeted therapy.

  • Programmed cell death-1 (PD1)
  • programmed death-1 ligand-1 (PDL1)
  • gastric cancer

Surgical resection with lymphadenectomy is the standard treatment for patients with stage II/III gastric cancer. In Japan, postoperative adjuvant chemotherapy is considered effective for stage II/III gastric cancer. However, recurrent disease after surgery is observed in 30% of patients with stage III disease (1). Thus, more aggressive therapy after surgery, including a combination of chemotherapeutic agents or molecular-targeted therapy, is required (2).

Cell-surface molecule programmed death 1 (PD1) inhibits T-cell co-stimulation and is a key molecule in the regulation of peripheral immunotolerance (3, 4). PDL1, which is one of a number of PD1 ligands, has a much broader tissue distribution than PD1 and can deliver inhibitory signals to PD1+ T-cells to suppress immune responses (4, 5). PDL1 is widely expressed in cancer, where it contributes to immune evasion and facilitates tumor growth (6). Recently, targeting the inhibitory PDL1/PD1 interaction using a monoclonal antibody was shown to result in striking antitumor activity in patients with melanoma in a phase I study (7, 8).

We previously showed that gastric cancer cells have the potential to react with cytotoxic T-lymphocytes (9). Furthermore, we showed that immunochemotherapy after surgery might be effective for patients with gastric cancer lymph node metastasis (10). Thus, gastric cancer cells may be immunogenic and the clinical effect of an antibody to PD1 antibody on the survival of patients with gastric cancer may possibly be shown in the near future. The aim of the present study was to investigate the impact of the expression of PDL1 and PD1 in tumors on the survival of patients with gastric cancer in order to determine which patients might be appropriate for immune checkpoint-targeted therapy.

Materials and Methods

Clinical samples. Tumor samples were obtained from 431 patients (mean age=66 years) who underwent surgical resection for gastric cancer without preoperative chemotherapy at the Department of Surgical Oncology, Osaka City University Hospital, between 1997 and 2010. Tumors were diagnosed histologically based on the Third Edition of the Japanese Classification of Gastric Carcinoma (11). Informed consent was obtained from all patients.

Immunohistochemistry. Tumor specimens in paraffin-embedded blocks were cut into 4-μm-thick sections. For antigen retrieval, the samples were autoclaved in 0.01 M citrate (pH 6.0) at 121°C for 15 min. The samples were then deparaffinized in xylene and rehydrated using a graded series of ethanol. The slides were then washed twice for 5 min per wash in phosphate-buffered saline (PBS). Endogenous peroxidase activity was blocked with absolute methanol containing 3% hydrogen peroxide for 15 min. After washing in PBS, the samples were microwaved for 10 min for the purpose of antigen retrieval. Nonspecific binding was blocked using a non-specific staining blocking reagent (Dako, Kyoto, Japan). The samples were then reacted with rabbit polyclonal anti-PDL1 (#58810, 1:50 dilution; Abcam, Tokyo, Japan) or with mouse monoclonal anti-PD1 (#52587, 1:50 dilution; Abcam) at 4°C overnight, and were subsequently washed with PBS for 10 min. The samples were then incubated with secondary antibodies for 10 min at room temperature. The secondary antibody was a biotin-labeled goat anti-rabbit IgG (1:500; Nichirei, Tokyo, Japan) for anti-PDL1 and a biotin-labeled rabbit anti-mouse IgG+IgM+IgA (1:500, Nichirei, Tokyo, Japan) for anti-PD1. After washing in PBS, signals were visualized by incubation with 3-3’-diaminobenzidine for 5 min, and the slides were counterstained with hematoxylin before mounting. All reactions were performed using appropriate positive and negative controls. The expression of PDL1 was evaluated according to the percentage of the stained cell. We defined samples with less than 10% of positive cells, 10-50% of positive cells, more than 51% of positive cells as weak, moderate, strong expression respectively. For analysis of the expression of PD1, the total number of PD1+ cells was counted in three high-power fields (HPFs) within tumor samples. Samples with a mean of more than five PD1+ cells were classified into a high-infiltration (PD1 high) group. Two experienced investigators, who were blinded to the clinical follow-up data, independently analyzed the expression of these molecules.

Statistical analysis. The Mann–Whitney test was used to assess the associations between the expression of PDL1 and PD1 and clinicopathological features. Correlation of tumor PDL1 expression with infiltration of PD1+ cells was investigated by using the Wilcoxon rank sum test.

The Kaplan–Meier method was used to construct the overall survival curves and a log-rank test was used to assess the significance of differences in survival. A Cox proportional regression model was used for univariate and multivariate analyses of prognostic factors. A p-value of less than 0.05 was considered statistically significant. Each statistical analysis was performed using JMP software (SAS Institute, Cary, NC, USA).

Results

Expression of PDL1 and PD1 in gastric cancer. In total, 431 patients with gastric cancer who underwent surgical resection were included in the study. The characteristics of the patients are summarized in Table I. The median follow-up time was 34 months. Out of these patients, 165 were diagnosed with stage II/III disease and 27% of these had received postoperative adjuvant chemotherapy.

Immunohistochemical staining detected PDL1 in the cytoplasm of tumor cells (Figure 1A-C). Strong staining of PDL1 was present in 128 (29.6%) and weak staining was observed in 113 (27.3%) of the tumor samples. The remaining samples showed moderate PDL1 staining. Strong staining of PDL1 was significantly associated with depth of invasion (pT), lymphatic invasion, venous invasion, lymph node metastasis, and pathological stage (Table II). No significant association was detected between PDL1 staining level and histology or macroscopic type. PD1 was detected in stromal lymphocytes (Figure 1D and E). With regard to PD1 expression, a cut-off of 5, the median number of PD1-positive cells, was used to define ‘low’ versus ‘high’ expression. PD1 expression was significantly higher in tissues with lymph node metastasis, serosal invasion and late pathological stage than in tissues without lymph node metastasis or early stage cancer (Table II). No significant difference was observed in PD1 expression level by histological type. Strong staining of PDL1 was associated with high infiltration of PD1+ cells. Out of 128 tumors with strong staining of PDL1, 96 (75%) had a high density of PD1+ cells. In contrast, in tumors that were weak for PDL1 staining, the percentage of tumors with a high density of PD1+ cells was only 26.5%. A significant positive correlation was observed between PDL1 expression and PD1+ cell infiltration (Figure 2).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Summary of patient characteristics (N=431).

Impact of PDL1 and PD1 expression on the survival of patients with gastric cancer. We evaluated the effect of PDL1 and PD1 expression in the primary tumor on patient prognosis. In this analysis, we also defined strong staining of PDL1 as positive and defined moderate and weak staining of PDL1 as negative for PDL1 expression. With regard to PD1, we defined high infiltration as positive and defined low infiltration as negative. Univariate Cox regression analysis showed that poor tumor differentiation, lymph node metastasis (pN), depth of invasion, PDL1 expression and PD1 infiltration were negative prognostic factors for patients overall (Table III). In multivariate analysis, pT, pN, lymphatic invasion and PDL1 expression were independent prognostic factors (Table III).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Correlation of PD1 and PDL1 expression with clinicopathological features of patients with gastric cancer.

Overall survival according to PD1 and PDL1 expression is shown by Kaplan–Meier curves in Figure 3. Patients with strong staining of PDL1 in tumor had significantly poorer prognosis compared to patients with weak staining (Figure 3A). With regard to PD1, patients with a high level of PD1+ cell infiltration had a worse prognosis compared to those with a low level of infiltration (Figure 3B). As shown in Figure 3C, the overall survival of patients whose tumors were positive for both PDL1 and PD1 was significantly worse than that for patients whose tumors were negative for both molecules, indicating that a positive relationship between PDL1 and PD1 could reflect on prognosis. In sub-group analysis based on pathological stage, PDL1 expression was not associated with prognosis in stage I and IV; however, it was significantly associated with overall survival in stage II/III cancer (Figure 4). The survival rate at 1, 2, and 5 years following gastrectomy was 91.9%, 67.0% and 33.2%, respectively, for patients with strong tumor PDL1 staining compared with 90.9%, 85.4% and 69.2%, respectively, for patients with weak staining. In multivariate analysis, PDL1 expression was an independent prognostic factor for gastric cancer patients with stage II/III cancer (Table IV).

Discussion

In the present study, we obtained the following findings. First, weak tumor staining of PDL1 was associated with significantly better overall survival than strong tumor staining of PDL1 in patients with gastric cancer. Secondly, expression of PDL1 in the primary tumor was correlated with tumor-infiltrating PD1+ cells. Thirdly, we showed that PDL1 expression was an independent prognostic factor for patients with stage II/III cancer who underwent curative resection surgery. Our results suggest that PDL1 expression might be a good prognostic factor for consideration of immunotherapy using an immune checkpoint antibody for patients with stage II/III gastric cancer.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Immunohistochemical staining for programmed death-1 ligand-1 (PDL1) and programmed death-1 (PD1) in gastric cancer tissue. A-C: Representative immunohistochemical staining for PDL1 expression in gastric cancer. Samples were divided into three groups according to the intensity of PDL1 expression: weak (A), moderate (B), and strong (C) staining of PDL1 (at ×400 magnification). D and E: Representative immunohistochemical staining for PD1+ cells infiltrating gastric cancer tissue: low infiltration (D) and high infiltration (E) (original magnification ×200).

It has been demonstrated that tumor cells are capable of up-regulating their expression of PDL1, thereby providing inhibitory signals to suppress the cytotoxic activity of CD8+ T-cells (12). Although the precise mechanism by which intra-tumoral PDL1 worsens a patient's prognosis remains to be determined, PDL1 has been reported to be expressed in different cancer types including in breast, ovarian, pancreastic, esophageal, colorectal and gastric cancer (6, 13, 14-16). Furthermore, PDL1 expression by tumor cells has been reported to strongly correlate with poor prognosis (14).

We previously reported that immunosuppressive status within a tumor was associated with progression of gastric cancer (17, 18). In addition, we showed that immunotherapy might be effective for gastric cancer (10). We, therefore, hypothesized that gastric cancer may be relatively immunogenic. Our study showed that the expression level of PDL1 was significantly correlated with the density of PD1+ cell infiltration. Saito et al. demonstrated very high up-regulation of PD1 expression on T-cells in gastric cancer tissue and they suggested that the cancer cells themselves could affect PD1 and PDL1 expression in the local environment (19). Our results suggest that PD1 on the surface of intra-tumoral infiltrated T-cells might be induced in response to an inflammatory environment that is created by cancer cells.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Univariate and multivariate Cox regression analysis of clinicopathological and molecular features for overall survival in patients with gastric cancer.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Univariate and multivariate Cox regression analysis of clinicopathological and molecular features for overall survival of patients with stage II/III gastric cancer.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Correlation of tumor Programmed Death-1 Ligand-1 (PDL1) expression with infiltration of programmed death-1 (PD1)-positive cells. The number of stained PD1+ T-cells within tumors with high, moderate, and weak staining of PDL1 was plotted. Each box indicates the first and upper quartiles, and the bar in each box indicates the median value. The number of PD1+ cells significantly increased according to the intensity of PDL1 staining. ***p<0.0001.

Immune checkpoint blockade with monoclonal antibodies directed at PD1 and PDL1 has emerged as a treatment for patients with advanced melanoma (7). As the population of patients who attain clinical benefit is relatively small, identification of a biomarker for response to this immunotherapy is critical. PDL1 expression has been considered as a predictive marker for tumor response to PD1 antibody treatment. Indeed, PDL1 expression is one of the eligibility criteria in the clinical study of PD1 antibody immunotherapy for several types of cancer. Although the safety and the efficacy of anti-PD1 treatment has been demonstrated in patients with advanced non-small cell lung cancer in a phase I study, the efficacy of such immunotherapy for gastric cancer has not been elucidated (20). We found a strong prognostic impact of PDL1 expression in pathological stage II/III cancer. Over 30% of patients with pathological stage II/III cancer often have recurrent disease after gastrectomy due to remnant cancer cells (1). Our results suggest that remnant tumor cells with low PDL1 expression might be attacked by tumor-specific cytotoxic T-cells after surgery, resulting in longer patient survival.

Our study has several limitations. One is the definition of PDL1 positivity. Distinction between PDL1 staining patterns (for example, membranous or cytosolic) and determination of cut-off values for the percentage of stained cells were difficult. Nevertheless, we showed that there were significant differences in overall survival among patients whose tumors were positive for both PD1 and PDL1 expression, were positive for either molecule, or were negative for both molecules, by examination of PD1 and PDL1 expression in the same section. Another limitation is that there may be a bias in the selection of patients since this was a retrospective study. In order to minimize such a potential bias, we did examine 431 consecutive samples.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Survival curves for patients with gastric cancer with different expression levels of programmed death-1 ligand-1 (PDL1) and Programmed Death-1 (PD1). The overall survival of patients with the indicated expression of PDL1 (A), PD1 (B), or combinations of PD1 and PDL1 expression (C), is indicated using Kaplan–Meier curves. The p-value was determined using the log-rank test. Patients with strong PDL1 staining had a poorer prognosis than those with weak or moderate PDL1 staining (A). Patients with high PD1+ cell infiltration had a poorer prognosis than those with low PD1+ cell infiltration (B). Patients that were negative for both PD1 and PDL1 had a better prognosis than patients that were positive for both molecules (C).

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Survival curves according to programmed death-1 ligand-1 (PDL1) expression in different pathological stages of gastric cancer. The overall survival of patients with weak or strong PDL1 staining in pathological stage I (A), II (B), III (C), IV (D) or II/III (E) gastric cancer is indicated using Kaplan–Meier curves. The p-value was determined using the log-rank test. Patients with strong PDL1 staining had a worse prognosis compared to those with weak PDL1 staining in pathological stage II/III cancer.

In conclusion, PDL1 was found to be an independent prognostic factor for patients with gastric cancer especially for those with pathological stage II/III cancer. Our study suggests that therapeutic targeting of PDL1 in gastric cancer might provide an antitumor effect and reduce the metastatic risk for patients with stage II/III gastric cancer.

  • Received May 28, 2015.
  • Revision received July 6, 2015.
  • Accepted July 9, 2015.
  • Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Sasako M,
    2. Sakuramoto S,
    3. Katai H,
    4. Kinoshita T,
    5. Furukawa H,
    6. Yamaguchi T,
    7. Nashimoto A,
    8. Fujii M,
    9. Nakajima T,
    10. Ohashi Y
    : Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29: 4387-4393, 2011.
    OpenUrlPubMed
  2. ↵
    1. Bang YJ,
    2. Van Cutsem E,
    3. Feyereislova A,
    4. Chung HC,
    5. Shen L,
    6. Sawaki A,
    7. Lordick F,
    8. Ohtsu A,
    9. Omuro Y,
    10. Satoh T,
    11. Aprile G,
    12. Kulikov E,
    13. Hill J,
    14. Lehle M,
    15. Ruschoff J,
    16. Kang YK
    : Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase III, open-label, randomised controlled trial. Lancet 376: 687-697, 2010.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Keir ME,
    2. Butte MJ,
    3. Freeman GJ,
    4. Sharpe AH
    : PD1 and its ligands in tolerance and immunity. Annual review of immunology 26: 677-704, 2008.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Thompson RH,
    2. Kuntz SM,
    3. Leibovich BC,
    4. Dong H,
    5. Lohse CM,
    6. Webster WS,
    7. Senupta S,
    8. Frank I,
    9. Parker AS,
    10. Zincke H,
    11. Blute ML,
    12. Sebo TJ,
    13. Cheville JC,
    14. Kwon ED
    : Tumor B7-H1 is associated with poor prgnosis in renal cell carcinoma patients with long-term follow-up. Cancer research 66: 3381-3385, 2006.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Dong H,
    2. Strome SE,
    3. Salomao DR,
    4. Tamura H,
    5. Hirano F,
    6. Flies DB,
    7. Roche PC,
    8. Lu J,
    9. Zhu G,
    10. Tamada K,
    11. Lennon VA,
    12. Celis E,
    13. Chen L
    : Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature medicine 8: 793-800, 2002.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Ohigashi Y,
    2. Sho M,
    3. Yamada Y,
    4. Tsurui Y,
    5. Hamada K,
    6. Ikeda N,
    7. Mizuno T,
    8. Yoriki R,
    9. Kashizuka H,
    10. Yane K,
    11. Tsushima F,
    12. Otsuki N,
    13. Yagita H,
    14. Azuma M,
    15. Nakajima Y
    : Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 11: 2947-2953, 2005.
    OpenUrlPubMed
  7. ↵
    1. Brahmer JR,
    2. Tykodi SS,
    3. Chow LQ,
    4. Hwu WJ,
    5. Topalian SL,
    6. Hwu P,
    7. Drake CG,
    8. Camacho LH,
    9. Kauh J,
    10. Odunsi K,
    11. Pitot HC,
    12. Hamid O,
    13. Bhatia S,
    14. Martins R,
    15. Eaton K,
    16. Chen S,
    17. Salay TM,
    18. Alaparthy S,
    19. Grosso JF,
    20. Korman AJ,
    21. Parker SM,
    22. Agrawal S,
    23. Goldberg SM,
    24. Pardoll DM,
    25. Gupta A,
    26. Wigginton JM
    : Safety and activity of anti-PDL1 antibody in patients with advanced cancer. The New England journal of medicine 366: 2455-2465, 2012.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Topalian SL,
    2. Hodi FS,
    3. Brahmer JR,
    4. Gettinger SN,
    5. Smith DC,
    6. McDermott DF,
    7. Powderly JD,
    8. Carvajal RD,
    9. Sosman JA,
    10. Atkins MB,
    11. Leming PD,
    12. Spigel DR,
    13. Antonia SJ,
    14. Horn L,
    15. Drake CG,
    16. Pardoll DM,
    17. Chen L,
    18. Sharfman WH,
    19. Anders RA,
    20. Taube JM,
    21. McMiller TL,
    22. Xu H,
    23. Korman AJ,
    24. Jure-Kunkel M,
    25. Agrawal S,
    26. McDonald D,
    27. Kollia GD,
    28. Gupta A,
    29. Wigginton JM,
    30. Sznol M
    : Safety, activity, and immune correlates of anti-PD1 antibody in cancer. The New England journal of medicine 366: 2443-2454, 2012.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Iwauchi T,
    2. Tanaka H,
    3. Yamazoe S,
    4. Yashiro M,
    5. Yoshii M,
    6. Kubo N,
    7. Muguruma K,
    8. Sawada T,
    9. Ohira M,
    10. Hirakawa K
    : Identification of HLA-A*2402-restricted epitope peptide derived from ERAS oncogene expressed in human scirrhous gastric cancer. Cancer science 102: 683-689, 2011.
    OpenUrlPubMed
  10. ↵
    1. Ito G,
    2. Tanaka H,
    3. Ohira M,
    4. Yoshii M,
    5. Muguruma K,
    6. Kubo N,
    7. Yashiro M,
    8. Yamada N,
    9. Maeda K,
    10. Sawada T,
    11. Hirakawa K
    : Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I. Experimental and therapeutic medicine 3: 925-930, 2012.
    OpenUrl
  11. ↵
    1. Japanese Gastric Cancer Association
    : Japanese gastric cancer treatment guidelines 2010(ver.3).Gastric Cancer 14: 113-123, 2011.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Topalian SL,
    2. Drake CG,
    3. Pardoll DM
    : Targeting the PD1/B7-H1(PDL1) pathway to activate anti-tumor immunity. Current opinion in immunology 24: 207-212,
  13. ↵
    1. Droeser RA,
    2. Hirt C,
    3. Viehl CT,
    4. Frey DM,
    5. Nebiker C,
    6. Huber X,
    7. Zlobec I,
    8. Eppenberger-Castori S,
    9. Tzankov A,
    10. Rosso R,
    11. Zuber M,
    12. Muraro MG,
    13. Amicarella F,
    14. Cremonesi E,
    15. Heberer M,
    16. Iezzi G,
    17. Lugli A,
    18. Terracciano L,
    19. Sconocchia G,
    20. Oertli D,
    21. Spagnoli GC,
    22. Tornillo L
    : Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 49: 2233-2242, 2013.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Geng Y,
    2. Wang H,
    3. Lu C,
    4. Li Q,
    5. Xu B,
    6. Jiang J,
    7. Wu C
    : Expression of costimulatory molecules B7-H1, B7-H4 and FOXP3(+) Tregs in gastric cancer and its clinical significance. International journal of clinical oncology 20: 273-281, 2015.
    OpenUrlPubMed
    1. Muenst S,
    2. Schaerli AR,
    3. Gao F,
    4. Daster S,
    5. Trella E,
    6. Droeser RA,
    7. Muraro MG,
    8. Zajac P,
    9. Zanetti R,
    10. Gillanders WE,
    11. Weber WP,
    12. Soysal SD
    : Expression of programmed death ligand 1 (PDL1) is associated with poor prognosis in human breast cancer. Breast cancer research and treatment 146: 15-24, 2014.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Wang L,
    2. Ma Q,
    3. Chen X,
    4. Guo K,
    5. Li J,
    6. Zhang M
    : Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma. World journal of surgery 34: 1059-1065, 2010.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Yoshii M,
    2. Tanaka H,
    3. Ohira M,
    4. Muguruma K,
    5. Iwauchi T,
    6. Lee T,
    7. Sakurai K,
    8. Kubo N,
    9. Yashiro M,
    10. Sawada T,
    11. Hirakawa K
    : Expression of Forkhead box P3 in tumour cells causes immunoregulatory function of signet ring cell carcinoma of the stomach. British journal of cancer 106: 1668-1674, 2012.
    OpenUrlPubMed
  17. ↵
    1. Yoshii M,
    2. Tanaka H,
    3. Ohira M,
    4. Muguruma K,
    5. Sakurai K,
    6. Kubo N,
    7. Yashiro M,
    8. Sawada T,
    9. Hirakawa K
    : Association of MHC class I expression and lymph node metastasis of gastric carcinoma. Hepato-gastroenterology 60: 611-615, 2013.
    OpenUrlPubMed
  18. ↵
    1. Saito H,
    2. Kuroda H,
    3. Matsunaga T,
    4. Osaki T,
    5. Ikeguchi M
    : Increased PD1 expression on CD4+ and CD8+ T-cells is involved in immune evasion in gastric cancer. Journal of surgical oncology 107: 517-522, 2013.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Garon EB,
    2. Rizvi NA,
    3. Hui R,
    4. Leighl N,
    5. Balmanoukian AS,
    6. Eder JP,
    7. Patnaik A,
    8. Aggarwal C,
    9. Gubens M,
    10. Horn L,
    11. Carcereny E,
    12. Ahn MJ,
    13. Felip E,
    14. Lee JS,
    15. Hellmann MD,
    16. Hamid O,
    17. Goldman JW,
    18. Soria JC,
    19. Dolled-Filhart M,
    20. Rutledge RZ,
    21. Zhang J,
    22. Lunceford JK,
    23. Rangwala R,
    24. Lubiniecki GM,
    25. Roach C,
    26. Emancipator K,
    27. Gandhi L,
    28. Investigators K
    : Pembrolizumab for the treatment of non-small-cell lung cancer. The New England journal of medicine 2015.
PreviousNext
Back to top

In this issue

Anticancer Research: 35 (10)
Anticancer Research
Vol. 35, Issue 10
October 2015
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer
TATSURO TAMURA, MASAICHI OHIRA, HIROAKI TANAKA, KAZUYA MUGURUMA, TAKAHIRO TOYOKAWA, NAOSHI KUBO, KATSUNOBU SAKURAI, RYOSUKE AMANO, KENJIRO KIMURA, MASATSUNE SHIBUTANI, KIYOSHI MAEDA, KOSEI HIRAKAWA
Anticancer Research Oct 2015, 35 (10) 5369-5376;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer
TATSURO TAMURA, MASAICHI OHIRA, HIROAKI TANAKA, KAZUYA MUGURUMA, TAKAHIRO TOYOKAWA, NAOSHI KUBO, KATSUNOBU SAKURAI, RYOSUKE AMANO, KENJIRO KIMURA, MASATSUNE SHIBUTANI, KIYOSHI MAEDA, KOSEI HIRAKAWA
Anticancer Research Oct 2015, 35 (10) 5369-5376;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • PD-1 Expression and its Correlation With Prognosis in Clear Cell Renal Cell Carcinoma
  • Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma
  • Clinical Significance of Tumor and Immune Cell PD-L1 Expression in Gastric Adenocarcinoma
  • The Clinical Significance of PD-L1/PD-1 Expression in Gastroenteropancreatic Neuroendocrine Neoplasia
  • Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer
  • The Prognostic Significance of the Tumor-infiltrating Programmed Cell Death-1+ to CD8+ Lymphocyte Ratio in Patients with Colorectal Cancer
  • Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy
  • Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging
  • Google Scholar

More in this TOC Section

  • Inhibiting miR-33b-5p Enhances Chemoresistance in Lung Adenocarcinoma by Targeting YWHAH to Regulate Epithelial-mesenchymal Transition
  • Relationship Between Mediterranean Diet, Cardiovascular Risk Factors, and Meningiomas: A Retrospective Study
  • PARP Inhibitor Sensitizes BRCA-mutant Pancreatic Cancer to Oxaliplatin by Suppressing the CDK1/BRCA1 Axis
Show more Experimental Studies

Similar Articles

Keywords

  • Programmed cell death-1 (PD1)
  • programmed death-1 ligand-1 (PDL1)
  • Gastric cancer
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire